Loading...
XSTOCLBIO
Market cap19mUSD
Dec 23, Last price  
8.86SEK
1D
2.07%
1Q
12.15%
Jan 2017
-12.28%
IPO
-8.63%
Name

Corline Biomedical AB

Chart & Performance

D1W1MN
XSTO:CLBIO chart
P/E
—
P/S
8.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.82%
Rev. gr., 5y
74.14%
Revenues
25m
+6.28%
5,999,3831,787,6271,683,2561,037,089947,000638,0001,563,0001,064,0003,696,0007,062,00023,550,00025,030,000
Net income
-2m
L
-911,471-2,487,798-2,512,187-5,845,275-5,248,000-7,810,000-6,793,000-9,540,000-7,287,000-6,916,0002,329,000-1,809,000
CFO
886k
P
0-2,759,348-2,318,929-4,231,183-7,211,000-4,978,000-4,104,000-13,839,000-5,066,000-4,835,000-6,452,000886,000
Earnings
Feb 12, 2025

Profile

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
URL
https://www.corline.se/home
IPO date
Jun 03, 2015
Employees
14
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
25,030
6.28%
23,550
233.47%
7,062
91.07%
Cost of revenue
(3,350)
824
(2,040)
Unusual Expense (Income)
NOPBT
28,380
22,726
9,102
NOPBT Margin
113.38%
96.50%
128.89%
Operating Taxes
549
(6)
Tax Rate
2.42%
NOPAT
28,380
22,177
9,108
Net income
(1,809)
-177.67%
2,329
-133.68%
(6,916)
-5.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
537
26
50,634
BB yield
-0.17%
-0.01%
-16.97%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
4,341
Net debt
(17,013)
(26,211)
(41,636)
Cash flow
Cash from operating activities
886
(6,452)
(4,835)
CAPEX
(132)
(8,999)
(9,617)
Cash from investing activities
(10,621)
(8,999)
(9,561)
Cash from financing activities
537
26
47,126
FCF
39,070
11,355
8,999
Balance
Cash
17,012
26,210
41,635
Long term investments
1,000
1,000
1,000
Excess cash
15,762
25,034
41,283
Stockholders' equity
(61,877)
5,015
39,511
Invested Capital
155,193
89,574
52,723
ROIC
23.19%
31.17%
13.65%
ROCE
30.41%
24.03%
9.87%
EV
Common stock shares outstanding
21,677
21,491
20,440
Price
14.90
61.61%
9.22
-36.85%
14.60
0.43%
Market cap
322,992
63.01%
198,145
-33.60%
298,422
19.71%
EV
305,979
235,224
256,786
EBITDA
28,477
22,782
9,133
EV/EBITDA
10.74
10.33
28.12
Interest
26
13
Interest/NOPBT
0.09%
0.14%